期刊
CURRENT OPINION IN PHARMACOLOGY
卷 36, 期 -, 页码 107-113出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2017.09.009
关键词
-
资金
- Achaogen Inc.
- AiCuris GmbH
- Arsanis Inc.
- Cellceutix Corporation
- Cempra Pharmaceuticals
- Cidara Therapeutics Inc.
- Contrafect Corporation
- Debiopharm International SA
- Entasis Therapeutics
- Geom Therapeutics, Inc.
- GlaxoSmithKline
- Horizon
- Insmed Inc.
- Kalyra Pharmaceuticals
- Medicines Company
- Meiji Seika Pharma Co., Ltd.
- Melinta Therapeutics
- Merck Sharpe Dohme.
- Nabriva Therapeutics
- Naeja RGM Pharmaceuticals Inc.
- NuCana Biomed
- Paratek Pharmaceuticals
- Pernix Therapeutics
- Polyphor Ltd.
- Roche Bioscience
- Shionogi, Inc.
- Sofinnova Ventures, Inc.
- Spero Therapeutics
- Theravance Biopharma Pharmaceutica
- Tetraphase Pharmaceuticals
- VenatoRx
- Wockhardt Ltd.
- Zavante Therapeutics
Monte Carlo simulation is used to generate data for pharmacokinetic pharmacodynamic (PK-PD) target attainment analyses to assess antibacterial dosing regimens in early and late stage drug development. Careful consideration of the quality of data for pharmacokinetics, non-clinical PK-PD targets for efficacy, the choice of the bacterial reduction endpoint upon which the PK-PD target is based, variability in the PK-PD target, and effect site exposures ensures optimal dose selection. Relationships between drug exposure and efficacy and/or safety endpoints based on clinical data can also be applied to simulated data to support dose selection. These in silico analyses, conducted throughout drug development, provide the greatest opportunity to de-risk the development of antibacterial agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据